Current Report Filing (8-k)
May 26 2020 - 5:12PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported): May 26, 2020
Blonder Tongue Laboratories,
Inc.
(Exact Name of registrant as
specified in its charter)
Delaware
|
|
1-14120
|
|
52-1611421
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File
Number)
|
|
(I.R.S. Employer
Identification No.)
|
One Jake Brown Road, Old Bridge, New
Jersey 08857
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number,
including area code: (732) 679-4000
Not Applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, par value $.001
|
|
BDR
|
|
NYSE American
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
|
On May 26, 2020 Blonder Tongue Laboratories, Inc. (the “Company”)
and Robert J. Pallé, who served as the Company’s Chief Executive Officer and President during 2019 and was a “named
executive officer” for that year, executed a letter agreement (the “Agreement”) providing for the continued employment
of Mr. Pallé by the Company in a new role as Managing Director—Strategic Accounts, reporting to the Company’s
CEO. Mr. Pallé also continues his service as a member of the Company’s Board of Directors (the “Board”).
Under the Agreement, which the parties have agreed will have
an effective date of January 1, 2020, Mr. Pallé initially will be responsible for managing certain strategic customer and
supplier accounts and leading certain specific initiatives and programs. The scope of his duties will be subject to change from
time to time as determined by the Chief Executive Officer and/or the Board. Mr. Pallé’s compensation under the Agreement
will consist of a salary of $152,000 per year plus commissions based on net sales of certain products to specified customers of
the Company. His employment will be on an “at will” basis, and he will be required to devote no more than 25 hours
per week to fulfilling his duties under the Agreement. The health, life and disability insurance and other benefits currently
in effect for Mr. Pallé will continue in effect through December 31, 2020, assuming that he continue to remain eligible
for such benefits, and will be subject to modification only to the extent that the Company modifies such benefits for all senior-level
Company employees. The parties anticipate that Mr. Pallé’s employment will terminate on Dec 31, 2020 unless otherwise
extended by the parties.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
BLONDER TONGUE LABORATORIES, INC.
|
|
|
|
By:
|
/s/ Eric Skolnik
|
|
Eric Skolnik
|
|
Senior Vice President and Chief Financial Officer
|
Date: May 26, 2020
2
Blonder Tongue Laborator... (AMEX:BDR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Blonder Tongue Laborator... (AMEX:BDR)
Historical Stock Chart
From Sep 2023 to Sep 2024